SEC Form 4 · accession 0001144204-19-000502
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Shapiro
Officer — Chief Medical Officer
Period of report
Jan 1, 2019
Accepted (ET)
Jan 3, 2019 · 7:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 1, 2019 | F | 736 | $100.79 | D | 38,416 | D | |
| Common Stock | Jan 2, 2019 | M | 2,000 | $31.90 | A | 40,416 | D | |
| Common Stock | Jan 2, 2019 | S | 2,000 | $98.28 | D | 38,416 | D | |
| Common Stock | Jan 3, 2019 | S | 699 | $97.45 | D | 37,717 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF3 | $31.90 | Jan 2, 2019 | M | 2,000 | D | — | May 7, 2023 | Common Stock | 2,000 | 17,031 | D |
Explanation of responses
- F1Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock and restricted stock units.
- F2This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- F3This option is fully vested and exercisable.